Paying for cures:
Ensuring patient access and system sustainability

February 12, 2019 • Washington, DC

Image Image Image Image

Learn Precision Financing solutions with innovation leaders and national policymakers at this one-day conference

Hosted by MIT Center for Biomedical Innovation NEWDIGS Initiative


Image Image

Image

Paying for cures: Ensuring patient access and system sustainability

February 12, 2019 • Washington, DC

Image Image Image Image

Learn Precision Financing solutions with innovation leaders and national policymakers at this one-day conference

Hosted by MIT Center for Biomedical Innovation NEWDIGS Initiative

Image
Understand the future of curative therapies and their financing challenges

Learn new Precision Financing strategies and tools

Connect with system stakeholders to solve problems

In this one day conference, grasp the challenges and solutions to making cures accessible to patients and sustainable by the healthcare system.

A collaboration for practical solutions
The Paying for Cures conference will share research and recommendations compiled over nearly three years in the NEWDIGS Consortium at MIT. The collaboration included perspectives across the healthcare innovation spectrum to develop patient-centered, system-sustainable solutions.

See the research

Featured Keynotes

  • Senator Bill Cassidy

    Senator Bill Cassidy

  • Senator Sheldon Whitehouse

    Senator Sheldon Whitehouse

Also featuring

Janet Lambert (Alliance for Regenerative Medicine) • Marc Boutin (National Health Council) • Steve Usdin (BioCentury) • Trent Haywood (BCBSA) • Mike Ciarametaro (National Pharmaceutical Council) • Peter Staltonstall (NORD)

Sponsors

Image Image Image Image Image
Speakers
  • Joe Alvarnas
    M.D. VP Government Affairs, City of Hope

  • Usman “Oz” Azam
    President & CEO, TMUNITY

  • Tim Brent
    Sr. Director of Business Development, National Hemophilia Foundation

  • Marc Boutin
    National Health Council

  • Kim Caldwell
    Principal, Texas Star Healthcare Consulting, LLC (formerly Division Director, Medicare Drug Benefit Group, CMS; & Vice President of Pharmacy Professional Affairs, Humana)

  • Brian Carey
    Partner and Co-Chair Administrative Law Department, Foley-Hoag LLP

  • Senator Bill CassidySenator Bill Cassidy
    United States Senate

  • Mike Ciarametaro
    VP Research, National Pharmaceutical Council

  • Rena Conti
    Boston University

  • Bob Galvin
    GE Health Benefits

  • David Goldston
    Director, MIT Washington D.C. Office

  • Jonathan Gruber
    Ford Professor of Economics, MIT and Director, Health Care Program, National Bureau of Economic Research

  • Trent Haywood
    Sr. VP & Sr. Medical Officer, BCBSA

  • Gigi Hirsch, MD
    Executive Director, MIT Center for Biomedical Innovation NEWDIGS Initiative

  • Mehb Khoja
    President, Medical Risk Managers Inc.

  • Krishna Komanduri
    Kalish Family Chair, Professor of Medicine, Director, Sylvester Cancer Center Adult Stem Cell Transplant Program

  • Janet Lambert
    CEO, Alliance for Regenerative Medicine (ARM)

  • Peter Staltonstall
    National Organization for Rare Diseases (NORD)

  • Mark Trusheim

    Mark Trusheim
    MIT NEWDIGS Initiative

  • Steve Usdin
    Senior Editor at BioCentury

  • Krystyn Van Vliet
    Associate Provost and Professor of DMSE and BE, MIT

  • Senator Sheldon Whitehouse

    Senator Sheldon Whitehouse
    United States Senate

  • Colin M. Young, PhD
    Director Drug Development Pipeline Research, MIT FoCUS Project

Speakers

Joe Alvarnas
M.D. VP Government Affairs, City of Hope

Usman “Oz” Azam
President & CEO, TMUNITY

Marc Boutin
CEO, National Health Council

Tim Brent
Sr. Director of Business Development, National Hemophilia Foundation

Chuck Bucklar
Group Vice President, Commercial Operations, North America, BioMarin Pharmaceutical Inc.

Kim Caldwell
Principal, Texas Star Healthcare Consulting, LLC (formerly Division Director, Medicare Drug Benefit Group, CMS; & Vice President of Pharmacy Professional Affairs, Humana)

Brian Carey
Partner and Co-Chair Administrative Law Department, Foley-Hoag LLP

Lovena Chaput
Vice President, Managed Markets & Reimbursement, AveXis

Senator Bill Cassidy
United States Senate

Mike Ciarametaro
VP Research, National Pharmaceutical Council

Rena Conti
Associate Professor, Markets, Public Policy, and Law; Associate Research Director, Biopharma and Public Policy, Institute for Health System Innovation and Policy, Boston University Questrom School of Business

Gregory Daniel
Deputy Director & Clinical Professor, Fuqua School of Business, Duke Margolis Center for Health Policy, Washington D.C. Office

Bob Galvin
Chief Executive Officer, Equity Healthcare, Blackstone

David Goldston
Director, MIT Washington D.C. Office

Darin Gordon
President & CEO, Gordon & Associates (former Director, Tennessee Medicaid program-TennCare)

Jonathan Gruber
Ford Professor of Economics, MIT and Director, Health Care Program, National Bureau of Economic Research

Trent Haywood
Sr. VP & Sr. Medical Officer, BCBSA

Gigi Hirsch, MD
Executive Director, MIT Center for Biomedical Innovation NEWDIGS Initiative

Mehb Khoja
President, Medical Risk Managers Inc.

Krishna Komanduri
Kalish Family Chair, Professor of Medicine, Director, Sylvester Cancer Center Adult Stem Cell Transplant Program

Janet Lambert
CEO, Alliance for Regenerative Medicine (ARM)

Edmund Pezalla
CEO Enlightenment Bio-consulting (former Vice President, National Medical Director, Pharmaceutical Policy and Strategy, Aetna)

Peter Saltonstall
President and CEO, National Organization for Rare Diseases (NORD)

Michael Sherman
Chief Medical Officer, Harvard Pilgrim Health Care

Mark Trusheim
Strategic Director, NEWDIGS Initiative, MIT Center for Biomedical Innovation

Steve Usdin
Senior Editor at BioCentury

Krystyn Van Vliet
Associate Provost and Professor of DMSE and BE, MIT

Senator Sheldon Whitehouse
United States Senate

Colin M. Young, PhD
Director Drug Development Pipeline Research, MIT FoCUS Project

Agenda

Part 1: Understanding curative and durable therapies
Why are we here? The science, patients and system readiness for curative therapies

Cell & Gene Therapies Drug Development Pipeline

Part 2: Challenges to accessibility
Financial Challenges Imposed by Curative Therapies: Real or Imagined?

Keynote: Senator Cassidy

The FoCUS Project: Precision Financing Solutions

Part 3: Clearing the way for cures
Putting Theory into Practice

Identifying Opportunities for Enabling Precision Financing

Keynote: Senator Whitehouse

Registration
Register now

Registration is free but seating is limited. Please register early to reserve your seat.

LOCATION

National Press Club
529 14th St NW, Washington, DC 20045
February 12, 2019